MedPage Today -- SAN FRANCISCO -- Once-daily dosing of the protease inhibitor darunavir (Prezista) appeared to be at least as effective as twice-a-day regimens among treatment-experienced patients with no darunavir-associated resistance mutations, researchers reported here.
